SKP2 and non-small cell lung carcinoma: Notably, pre-treatment with necroptosis inhibitor Necrostatin-1 (Nec-1) significantly compromised cisplatin-reduced cell viability in Skp2-knockdown (Fig. 7b) and SZL P1-41-treated (Fig. 7c) A549R cells, suggesting that necroptosis could be involved in NSCLC cells’ resistance to cisplatin.